Traws Pharma
TRAW
13 hedge funds and large institutions have $1.36M invested in Traws Pharma in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and closing their positions.
44% more funds holding
Funds holding: 9 → 13 (+4)
10% less capital invested
Capital invested by funds: $1.51M → $1.36M (-$153K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$148K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$74.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$74.1K |
| 4 |
DCLA
Douglas C. Lane & Associates
New York
|
+$74.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$74.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$10K |
| 2 |
DA
Dunvegan Associates
Santa Barbara,
California
|
-$1K |
TRAW Hedge Fund Activity: Q4 2015 in Review
13 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2015, worth a combined $1.36M — down 10% from $1.51M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new TRAW positions and 0 closed out — a net gain of 4 holders — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $148K. The largest seller was Bank of America, cutting an estimated $10K.
- 13 institutional investors held Traws Pharma (TRAW) as of Q4 2015, up from 9 in Q3 2015.
- Funds reported $1.36M of Traws Pharma stock for Q4 2015, down 10% quarter-over-quarter.
- 4 funds opened new Traws Pharma positions in Q4 2015 and 0 closed out, a net change of +4 holders.
- The largest Traws Pharma buyer in Q4 2015 was Renaissance Technologies, an estimated $148K added.
- The largest Traws Pharma seller in Q4 2015 was Bank of America, an estimated $10K sold.
Based on aggregated 13F filings for Q4 2015.